Table 2.

Unit costs and disutility weights

	Unit costs (£)		Utility weights
Canagliflozin	476.93		N/A
SoC in canagliflozin arm	259.40		N/A
SoC in placebo arm	259.18		N/A
Test costs	2.64		N/A
Intercept	N/A		0.785 [33]
Kidney	Event	Annual
DKD stage 1	0	189 [24]	− 0.15 [31]
DKD stage 2	0	189 [24]	− 0.15 [31]
DKD stage 3a	0	1580 [24]	− 0.20 [31]
DKD stage 3b	0	1580 [24]	− 0.20 [31]
DKD stage 4	0	3694 [24]	− 0.26 [31]
DKD stage 5	0	5764 [24]	− 0.27 [31]
Dialysis	0	27,270 [1]	− 0.53 [32]
Transplant	32,317	8519 [1]	− 0.29 [32]
CV
Nonfatal MI	6069 [30]	918 [30]	− 0.06 [33]
Nonfatal stroke	6618 [30]	979 [30]	− 0.16 [33]
HHF	1897 [30]	1601 [30]	− 0.11 [33]
Adverse events
GMI male	56 [34]	–	− 0.0046 [35]
GMI female	52 [34]	–	− 0.0046 [35]
UTI	99 [34]	–	− 0.0043 [35]
DKA	2052 [36]	–	− 0.0091 [37]
LEA	3808 [36]	1039 [36]	− 0.169 [33, 38]

CV cardiovascular, DKA diabetic ketoacidosis, DKD diabetic kidney disease, GMI genital mycotic infections, HHF hospitalization for heart failure, LEA lower extremity amputation, MI myocardial infarction, SoC standard of care, UTI urinary tract infection